Table 1 Clinical characteristics of controls and patients who survived sepsis
From: Sepsis-induced long-term immune paralysis – results of a descriptive, explorative study
Control (n = 8) | Sepsis (n = 8) | |
|---|---|---|
Age, median (range) | 59 (34–85) | 60 (36–82 |
Male sex | 5 (62.5) | 5 (62.5) |
Body mass index, kg/m2, median (range) | 26.4 (18.1–34.3) | 24.4 (22.2–40.4) |
Time since sepsis, months, median (range) | 26 (9–52) | |
Infection focus responsible for sepsis | ||
Urogenital | 4 (50) | |
necrotizing fasciitis | 2 (25) | |
Pulmonary | 1 (12.5) | |
Endoprothesis infection | 1 (12.5) | |
Morbidities (current and past) | ||
Heart and circulation | ||
Myocardial infarction | 2 (25) | 2 (25) |
Myocarditis | 0 (0) | 0 (0) |
Stroke | 1 (12.5) | 0 (0) |
Pulmonary artery embolism | 0 (0) | 0 (0) |
Thrombosis | 0 (0) | 0 (0) |
Airway and lung | ||
Asthma | 0 (0) | 0 (0) |
chronic bronchitis | 0 (0) | 2 (25) |
Pneumonia | 0 (0) | 2 (25) |
Exacerbation of chronic obstructive pulmonary disease | 0 (0) | 1 (12.5) |
Kidney | ||
Insufficiency | 1 (12.5) | 1 (12.5) |
Pyelonephritis | 0 (0) | 1 (12.5) |
Glomerulonephritis | 0 (0) | 0 (0) |
Gastrointestinal tract and metabolism | ||
Chronic inflammatory bowel disease | 0 (0) | 0 (0) |
Ulcus | 0 (0) | 1 (12.5) |
Gastritis | 1 (12.5) | 1 (12.5) |
Diabetes | 3 (37.5) | 3 (37.5) |
Current medications | 6 (75) | 7 (87.5) |
Anticoagulants | 0 (0) | 3 (37.5) |
Anti-platelet agents | 5 (62.5) | 3 (37.5) |
Antihypertensive medication | 2 (25) | 5 (62.5) |
Diuretics | 1 (12.5) | 4 (50) |
Diabetes medication | 3 (37.5) | 3 (37.5) |
Insulin | 2 (25) | 3 (37.5) |